Cogent Biosciences(COGT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, suf icient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., August 6, 2024 – Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined dis ...